Evidence map›Paper›PMID 41915070›Full record

ReviewAnnals of hematology2026

Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy.

Mutaz Jamal Al-Khreisat, Waleed K Abdulsahib, Ihsan Khudhair Jasim, H Malathi, Pradeepta Sekhar Patro, D Alex Anand, Gunjan Mukherjee, Aashna Sinha, Dilnoz Buriyeva

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mutaz Jamal Al-KhreisatFaculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
Waleed K AbdulsahibDepartment of Pharmacology and Toxicology, College of Pharmacy, Al Farahidi University, Baghdad, Iraq. waleedk.abdulsahib@uoalfarahidi.edu.iq.ORCID http://orcid.org/0000-0002-8851-5783
Ihsan Khudhair JasimDepartment of Pharmaceutics, Faculty of Pharmacy, Al-Turath University, Baghdad, Iraq.
H MalathiDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Pradeepta Sekhar PatroDepartment of Immunology, IMS and SUM Hospital, Siksha 'O' Anusandhan, Bhubaneswar, 751003, Odisha, India.
D Alex AnandDepartment of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Gunjan MukherjeeUniversity Institute of Biotechnology, Chandigarh University, Mohali, Punjab, India.
Aashna SinhaSchool of Applied and Life Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, Uttarakhand, India.
Dilnoz BuriyevaDepartment of Medicine, Termez University of Economics and Serviсe, Termez, Uzbekistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has revolutionized cancer treatment, offering durable responses across various malignancies. However, blood cancers present unique challenges due to significant heterogeneity, an immunosuppressive tumor microenvironment (TME), and potent mechanisms of immune evasion. This review synthesizes the current landscape of immune checkpoint blockade (ICB), evaluating both established agents and emerging targets (e.g., LAG-3, TIM-3, CD47) in hematologic malignancies. We critically examine the role of cancer stem cells (CSCs) in driving therapeutic resistance and recurrence, highlighting how aberrant signaling pathways (Wnt, Notch, m6A) fuel immune avoidance. Furthermore, we assess the transformative potential of cellular immunotherapies, specifically CAR-T and CAR-NK cells, proposing strategies to enhance their persistence and safety. By integrating insights from recent preclinical and clinical studies, this report provides a roadmap for developing rational, multi-pronged combination strategies that disrupt the “resistance ecosystem” of blood cancers, paving the way for personalized curative regimens.

Indexed as

Hematologic NeoplasmsImmune Checkpoint InhibitorsImmunotherapyAnimalsCombined Modality TherapyHumansImmunotherapy, AdoptiveNeoplastic Stem CellsSignal TransductionTumor MicroenvironmentImmune Checkpoint InhibitorsBlood cancersCancer stem cellsCombination immunotherapyImmune checkpoint targetsTumor microenvironment

Identifiers

PMID41915070
PMCPMC13038690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.